Partial
Mostly Aligned
Patient Risk:
Low
Summary
The claims largely align on mechanism (PPARα activation) and lipid effects (TG/LDL reduction with HDL increase) as described in the label's 12.1/12.2 sections. However, there are significant gaps: no label support for other lipid-lowering classes, real-world procurement/patent/generic information, or purchasing prescriptions. Important safety-related topics (contraindications, warnings/precautions, interactions, specific populations) are not addressed in the provided extracts, impacting overall alignment.
Category Scores
Accurate Statements
It works by activating peroxisome proliferator-activated receptor alpha (PPARα), which influences lipid metabolism.
12.1
This mechanism helps to lower triglyceride levels and, to a lesser extent, LDL cholesterol, while increasing HDL cholesterol.
12.2
Unsupported Statements
Fenofibrate is a fibric acid derivative.
Label does not explicitly classify fenofibrate as a fibric acid derivative in the provided sections.
Besides fenofibrate, other classes of drugs are used for cholesterol management.
Not discussed in the provided label sections.
These include statins, PCSK9 inhibitors, bile acid sequestrants, and ezetimibe.
Not listed in the provided label sections.
Patent expiry dates for specific fenofibrate formulations and brand names determine when generic versions can enter the market.
Patent statuses and expiry timelines are not addressed in the provided label sections.
Information on patent statuses and expiry timelines for various fenofibrate products can be found on resources like DrugPatentWatch.com [1].
External patent-status resources are not referenced in the provided label sections.
Numerous pharmaceutical manufacturers produce generic fenofibrate.
No manufacturer/generic information is included in the provided sections.
Some common manufacturers include Teva Pharmaceuticals, Mylan (now Viatris), and Aurobindo Pharma.
No manufacturer-specific information is present in the provided sections.
Fenofibrate can be purchased at most retail pharmacies.
Purchase channels are not addressed in the label sections provided.
It is also available through online pharmacies.
Not addressed in the provided label sections.
A prescription from a healthcare provider is generally required to obtain fenofibrate.
No information about prescription requirements is present in the provided sections.
Contradictions
Important Omissions
Contraindications and safety
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Significant safety topics (contraindications, warnings/precautions, interactions, specific populations) are not addressed in the provided label extracts; no explicit safety content is evaluated here.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement